Management and outcome of EGFR mutant lung cancer with SARS-CoV-2 infection.
| Autor: | Kolluri S; Department of Medical Oncology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India., Panda SS; Department of Medical Oncology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India., Panda A; Department of Radiology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India., Singh SK; Department of Medicine, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Jul-Sep; Vol. 19 (5), pp. 1454-1456. |
| DOI: | 10.4103/jcrt.JCRT_1205_21 |
| Abstrakt: | The world and India, in particular, have been grappling with the coronavirus disease (COVID-19) pandemic for more than a year now. The simultaneous presence of active COVID-19 infection with lung cancer poses both a diagnostic and therapeutic dilemma, because of similar clinical, radiological features along with increased susceptibility to ICU admissions and death. We present the case of a metastatic EGFR mutant lung cancer patient who was started on Gefitinib during active COVID-19 infection. He had made a complete recovery from COVID-19 infection while achieving a partial response to therapy in terms of primary lung cancer. The case highlights the importance of active involvement of a medical oncologist in the care of all cancer patients with COVID-19 infection instead of the traditional holding of all therapy for cancer until COVID-19 recovery as suggested by the majority of guidelines. Competing Interests: None |
| Databáze: | MEDLINE |
| Externí odkaz: |
|